Europe’s alternative protein sector recorded a sharp rebound in private investment during the first half of 2026, with companies raising €236 million, a 56% increase on the same period a year earlier. The figures, analysed by the Good Food Institute Europe (GFI Europe) using Net Zero Insights data, show that fermentation businesses attracted the bulk of the new capital as investors became more selective and increasingly focused on technologies capable of reaching commercial scale.
The increase comes against a challenging backdrop for the wider industry. Global alternative protein investment has remained under pressure, while companies developing plant-based meat, cultivated meat and fermentation technologies face high costs associated with manufacturing, regulation and market expansion.
Why has Europe’s alternative protein funding increased in 2026?
The European alternative protein sector’s funding increase was driven primarily by fermentation, which attracted substantially more investment than other parts of the industry during the first six months of 2026.
Precision fermentation companies raised €100 million, while biomass fermentation businesses secured €99 million. Together, the two categories accounted for approximately 84% of the €236 million raised by European alternative protein companies during the period.
The figures indicate a changing investment landscape. Rather than spreading capital widely across early-stage businesses, investors are increasingly directing larger amounts towards companies with established technologies, clearer routes to commercialisation and the potential to operate at industrial scale.
That shift is particularly important for fermentation businesses, where technological advances can support the production of proteins and other ingredients without relying directly on conventional livestock farming.
What role did fermentation play in the funding rebound?
Fermentation emerged as the clear leader within Europe’s alternative protein investment market during the first half of the year.
Precision fermentation companies alone raised €100 million in H1 2026, exceeding the €97 million they received throughout the whole of 2025. Biomass fermentation companies raised a further €99 million, compared with €61 million during 2025.
Several sizeable funding rounds helped drive the figures. French precision fermentation start-up Verley raised €25 million, while Dutch biomass fermentation company The Protein Brewery secured €18 million. These deals illustrate the industry’s movement towards fewer but larger financing rounds.
Fermentation companies also benefited from public support. They secured €67 million in grants during the first half of 2026, adding another layer of financial backing alongside private investment.
Why are investors becoming more selective?
The funding increase does not mean that capital is flowing freely across the entire alternative protein industry. Instead, available finance is becoming concentrated among companies that investors believe can demonstrate commercial viability.
The number of alternative protein investment deals fell sharply compared with the same period in 2025, even as the total amount raised in Europe increased. GFI Europe described investors as increasingly selective, backing fewer companies with larger amounts of capital.
That reflects a broader challenge facing the sector. Alternative protein businesses often require substantial investment to move from laboratory development and pilot production to commercial manufacturing. Building processing facilities, securing supply chains and achieving consistent production can require considerably more capital than early-stage research.
Consequently, investors are placing greater emphasis on scale-up plans, production reliability and evidence of market demand.
What happened to plant-based protein investment?
The recovery in overall European alternative protein funding masks a weaker performance from the plant-based segment.
Plant-based companies experienced a sharp decline in private investment during the first half of 2026. GFI Europe said many businesses in the category are now entering the difficult scale-up phase, although the second half of 2025 had been particularly strong for plant-based investment.
This distinction matters because plant-based products are already more established commercially than several newer alternative protein technologies. Companies are increasingly required to demonstrate that they can move beyond product launches and early consumer adoption towards profitable, large-scale operations.
Retail performance also remains uneven across Europe. Earlier industry analysis found that plant-based food volumes increased in France, Spain, Germany and Italy, while the Netherlands recorded a slight decline and the UK experienced a contraction.
The result is a more demanding environment for businesses seeking new investment.
How is cultivated meat performing in Europe?
Cultivated meat investment increased slightly during the first half of 2026, but remained below its 2023 peak.
The sector continues to face a particularly difficult commercialisation pathway because companies must combine biotechnology development with large-scale production, regulatory approval and consumer acceptance. Those requirements can make the journey from laboratory to supermarket significantly more capital-intensive than conventional food manufacturing.
The wider funding figures therefore suggest that cultivated meat companies have not yet regained the investment momentum seen earlier in the decade. The sector may need a more diversified funding model involving government grants, strategic corporate investment and other forms of finance alongside traditional venture capital.
How important is government funding to the alternative protein sector?
Public finance is becoming increasingly important as private investors become more cautious.
One example is Finland-based Solar Foods, which received a €78 million funding package from Business Finland comprising a €40 million grant and a €38 million loan to support the commercialisation of its Solein protein produced through fermentation.
Dutch company Vivici also received €12.5 million through the European Innovation Council Accelerator Programme, combining a €2.5 million grant with €10 million in equity. The funding is intended to help scale its precision-fermented dairy proteins.
Meanwhile, a Europe-wide consortium led by UK company Adamo Foods received a €10 million grant through the EU-funded Circular Bio-Based Europe Joint Undertaking to scale up fermentation-produced steak.
Such examples point towards a broader change in financing. Grants, loans and private equity are increasingly being combined to reduce the risks associated with building expensive production infrastructure.
Why does alternative protein investment matter for Europe?
The investment trend has implications beyond the food technology industry.
GFI Europe argues that alternative proteins could help diversify Europe’s food supply at a time when climate pressures and geopolitical disruption are exposing vulnerabilities in agricultural and international supply chains. Heatwaves and drought have placed additional pressure on food production, while conflicts continue to create uncertainty around global trade and logistics.
Europe has also developed a substantial research base. Between 2020 and 2025, European funders invested €1.3 billion in alternative protein research, while researchers produced more than 1,000 related papers in 2025 alone. The UK, Denmark and the Netherlands were among the leading European countries for research and innovation funding.
However, research capacity alone will not guarantee commercial success. Companies still need access to factories, specialist equipment, skilled workers, regulatory expertise and sufficient consumer demand.
What could happen to Europe’s alternative protein sector next?
The first-half funding figures provide evidence of renewed investor interest, but they also show that Europe’s alternative protein market is entering a more selective phase.
Fermentation appears best positioned to benefit from the current investment environment, particularly where companies can demonstrate scalable production and commercial applications. Plant-based and cultivated meat businesses, meanwhile, face greater pressure to prove that they can convert technological progress into sustainable revenues.
The coming months will therefore be important for the sector. Further private investment, government-backed financing and progress in commercial-scale facilities could determine whether the 2026 rebound develops into a sustained recovery. For Europe, the broader question is whether alternative proteins can move beyond promising technology and become a meaningful part of a more resilient food system.
